

ISPE is Changing with the Industry

ISPE's President and CEO Nancy S. Berg discusses changes at ISPE to better understand and act on the issues important to Members, their companies, regulators, and patients.



Here in the United States, we have been dealing with more than our share of influenza strains, several of which impacted a number of our Member sites along with our North American Office. During the worst of it, those who were vaccinated against influenza couldn't help but be thankful for the people, science, and technology that drive the development and manufacture of vaccines and other pharmaceutical products. This also brings to mind the role ISPE has in education and training of Members who help to bring new drugs and vaccines to patients faster and the impact of ISPE Members in the treatment, control and even eradication of sickness and diseases that were terminal just a few years ago.

Being a Member of ISPE and working in the pharmaceutical industry carries great responsibility. With this responsibility comes the obligation to be the best our industry can be—to stay ahead of trends and

technology, to work collaboratively in advancing technology utilization, to stimulate regulatory harmonization and to sustain a culture of quality that drives thinking beyond what is "acceptable" to what is "possible." ISPE shares these responsibilities. As the global professional society industry depends on to help achieve their goals, ISPE must be dedicated to understanding the needs of Members, their companies, regulators, and patients and be prepared to respond rapidly to opportunities. And, we are doing this. In the last issue, I mentioned that ISPE is leading a survey to better understand the root causes of drug shortages so we are better positioned to bring together industry and regulators to develop a risk-based approach to mitigating drug shortages. You also may have noticed that we have planned a number of *all new* conferences in 2013 that focus on the issues that will help Members develop professionally and be more aware of how industry is changing and how smart practices are driving innovation, process improvements, and higher quality worldwide.

ISPE's new Strategic and Business Plans direct other changes in how we offer benefits to Members and value to industry. I hope you are noticing how ISPE is involving, listening, and focusing its program and publication efforts on those issues that matter most.

I am particularly enthused about our efforts to grow and enhance our *Pharmaceutical Engineering* magazine. We know our Members have many publication and online

options and that our advertisers have a choice to run in our magazine or others. That is exactly why we must ensure that our publications remain relevant and world class--and why we must cover the most significant technical, engineering, and regulatory issues you are facing. We hope that over the last few months, you have noticed some subtle changes in the magazine articles and the addition of more regulatory news. Our Editorial Advisory Board is encouraging more Members to get involved and they have done an outstanding job of evolving our magazine. As we move through 2013, we will be building on the strengths of *Pharmaceutical Engineering* magazine and aligning it more specifically to the Society's strategic direction and to industry "hot" topics. We are also planning a minor facelift of the magazine's design and its web site. As we embark on these changes, we will be asking for your input. Watch for upcoming readership and advertiser surveys to arrive in your email. Interested in writing an article or contributing to a team paper? Let us know.

With a new event schedule, new guidance documents in development, an enhanced magazine, new Member groups, and engagement options for Members and their company leadership, ISPE will be the society industry views as relevant--and getting things done. Next month, I will discuss our technical and industry hot topics and how you can get involved in technical, engineering, and regulatory efforts that lead to industry's advancement. 